95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Immunol.
Sec. Viral Immunology
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1551775
Acute-Phase Proteins as Biomarkers of Inflammation in HIV Patients with Latent Tuberculosis: A Prospective Study
Provisionally accepted
Nathella Pavan Kumar 1*
Rajamariyam M 1
Arul Nancy 2 Bubby S Kumar3 3
Janakiram M 3
Shaik Fayaz Ahamed 2
Vinoth Kumar 4 vijila S 4 Sekar S 5 Kuralmozhi R 5 Dhanaraj Baskaran 1
Syed Hissar 1*
Subash Babu 2- 1 National Institute of Research in Tuberculosis (ICMR), Chennai, India
- 2 International Centers for Excellence in Research (ICER), Chennai, Tamil Nadu, India
- 3 Tamil Nadu State AIDS Control Society, Chennai, Tamil Nadu, India
- 4 Government Hospital of Thoracic Medicine, Chennai, Tamil Nadu, India
- 5 Rajiv Gandhi Govt. General Hospital, Chennai, India
Background: Tuberculosis (TB) remains the primary cause of death among individuals infected with HIV, increasing the risk of contracting TB by up to 26 times. This co-infection complicates the diagnosis and treatment of TB, ultimately affecting outcomes adversely. Acute-phase proteins (APPs), markers of inflammation, are significantly elevated during infections and serve as critical indicators of inflammation resulting from infectious diseases. In this prospective study, HIVpositive individuals at antiretroviral therapy (ART) clinics were screened for latent tuberculosis infection (LTBI) before starting isoniazid (INH) prophylaxis. Initially, 101 patients were enrolled, with 71 completing a six-month follow-up on INH prophylaxis. LTBI was diagnosed using QuantiFERON-TB Gold plus, categorizing participants as HIV-positive with LTBI (n=30) and HIV-positive without LTBI (n=71). Plasma levels of alpha-2-macroglobulin (A2M), C-reactive protein (CRP), serum amyloid P (SAP), haptoglobin, ferritin, soluble transferrin receptor (sTFR), apotransferrin, hepcidin, and S100A8/A9 were assessed using multiplex and quantikine assays.At baseline, levels of A2M, CRP, SAP, ferritin, hepcidin, and S100A9 were significantly elevated in HIV-positive patients with LTBI compared to those without LTBI (A2M, p=0.005; CRP, p<0.001; SAP, p=0.0006; ferritin, p<0.001; hepcidin, p=0.001; S100A9, p=0.001). Following six months of INH prophylaxis, significant reductions in these markers were observed in both groups, suggesting a reduction in inflammation.Our findings indicate that a baseline profile of APPs can effectively reflect the inflammatory status of HIV patients with LTBI. These inflammatory markers tend to decrease following effective INH treatment, underscoring their potential utility in monitoring disease progression and treatment response in this vulnerable population.
Keywords: Acute-Phase Proteins, biomarkers, HIV, LTBI, Isoniazid preventive treatment (IPT)
Received: 26 Dec 2024; Accepted: 01 Apr 2025.
Copyright: © 2025 Pavan Kumar, M, Nancy, Kumar3, M, Ahamed, Kumar, S, S, R, Baskaran, Hissar and Babu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Nathella Pavan Kumar, National Institute of Research in Tuberculosis (ICMR), Chennai, India
Syed Hissar, National Institute of Research in Tuberculosis (ICMR), Chennai, India
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.